Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
6.29 USD | +2.95% | -1.19% | -17.56% |
Summary
- On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
- According to Refinitiv, the company's ESG score for its industry is poor.
Strengths
- For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- Over the past four months, analysts' average price target has been revised upwards significantly.
- Over the past twelve months, analysts' opinions have been strongly revised upwards.
Weaknesses
- As estimated by analysts, this group is among those businesses with the lowest growth prospects.
- As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
- Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Life & Health Insurance
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-17.56% | 50.46M | D+ | ||
+10.58% | 80.6B | B- | ||
+8.42% | 51.13B | B+ | ||
+2.47% | 48.65B | B | ||
+10.21% | 42.58B | B+ | ||
+7.93% | 40.23B | B+ | ||
+20.33% | 38.14B | B | ||
+2.62% | 30.09B | B | ||
-7.27% | 27.79B | B- | ||
-20.20% | 25.5B | A- |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- NEUE Stock
- Ratings NeueHealth, Inc.